Highest-materiality recent filing
LB Pharmaceuticals appoints Joseph Miller as CFO, effective September 2, 2026
Joseph M. Miller named CFO; previously CFO of Aurinia Pharmaceuticals (April 2020–March 2026).
LB Pharma Q2 net loss $51.6M, cash $327.8M, NOVA-2 readout accelerated to H1 2027
Q2 2026 net loss $51.6M vs $4.9M; R&D expenses $44.1M vs $2.4M.
LB Pharmaceuticals raises $150M in private placement for pipeline expansion
Gross proceeds of ~$150M from sale of 3,577,560 shares at $34.94 and pre-funded warrants for 715,513 shares.
LB Pharma accelerates Phase 3 NOVA-2 topline to H1 2027; cash runway into Q2 2029
Topline results from Phase 3 NOVA-2 trial of LB-102 in schizophrenia now expected in first half of 2027, ahead of prior guidance.
LB Pharma Q1 net loss $19.1M; cash $365.6M; Phase 3 schizophrenia trial launched
Net loss of $19.1M in Q1 2026 vs $5.3M in Q1 2025; R&D expenses rose $11.2M to $14.6M.
LB Pharmaceuticals reports Q4 net loss $11.5M; cash $295.2M; advances LB-102 into Phase 3
Positive Phase 2 (NOVA-1) results for LB-102 in acute schizophrenia met primary endpoint; Phase 3 NOVA-2 initiated March 2026 with data expected H2 2027.
LB Pharmaceuticals raises $100M in private placement; Phase 2 MDD trial for LB-102 starts early 2027
Gross proceeds ~$100M from sale of 3.31M shares and 1.42M pre-funded warrants at $21.17/share.
LB Pharmaceuticals appoints Kaya Pai Panandiker as Chief Commercial Officer
Effective Nov 10, 2025; Panandiker previously CCO at Neumora Therapeutics.
LB Pharmaceuticals Reports Q3 2025 Results and Provides Trial Updates
Net loss narrowed to $3.6M in Q3 2025 from $14.2M in Q3 2024.
On September 15, 2026, LB Pharmaceuticals Inc (the “Company”) announced that Susan G. Kozauer, M.D. has been appointed to serve as the Company’s Chief Medical Officer, effective as of September 14, 2026 (the “Start Date”).
On September 3, 2026, LB Pharmaceuticals Inc (the “Company”) announced that Joseph M. Miller has been appointed to serve as the Company’s Chief Financial Officer, effective as of September 2, 2026
On June 8, 2026, she resigned from her position as Chief Medical Officer of the Company effective June 15, 2026 (the " Separation Date ").
Max materiality 0.85 · Median 0.60 · Most common event leadership